Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry patients

Journal of Inherited Metabolic Disease

Volumn 35, Issue 5, 2012, Pages 885-889

  Nicholls, Kathleen ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; AGE DISTRIBUTION; AGED; ALBUMINURIA; ARTERIAL STIFFNESS; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; MALE; PREDICTION; PULSE WAVE; RISK ASSESSMENT; SMOKING; SURVIVAL RATE; TREATMENT DURATION;

ADULT; AGED; AUSTRALIA; CARDIOVASCULAR DISEASES; COHORT STUDIES; FABRY DISEASE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; VASCULAR STIFFNESS; YOUNG ADULT;

EID: 84866736520     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-011-9428-z     Document Type: Article

References (22)

1. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812-2817
2. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, Target R, Levy BI (1995) Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 26:485-490
3. Bensalah M, Collin C, Boutouryrie P, Redheuil A, Germain DP, Mousseaux E (2011) Increased central aortic stiffness and left ventricular hypertrophy in Fabry disease. Eur Heart J 32(Suppl 1):50
4. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434-2439
5. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216-1221
6. Cartwright DJ, Cole AL, Cousins AJ, Lee PJ (2004) Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy. J Inherit Metab Dis 27(6):791-793
7. DeLoach SS, Townsend RR (2008) Vascular stiffness: its measurement and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol 3:184-192
8. Kalliokoski RJ, Kalliokoski KK, Penttinen M, Kantola I, Leino A, Viikari JS, Simell O, Nuutila P, Raitakari OT (2006) Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis 29:660-666, Epub 2006 Aug 12
9. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, Whybra C, Gal A, Bultas J, Beck M(2008) Onset and progression of the Anderson-Fabry disease related cardiomy-opathy. Int J Cardiol. 130:367-73
10. Laurent S, Katsahian S, Fassot C, Tropeano AI, Gautier I, Lalou B, Boutouyrie P (2003) Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 34:1203-1206
11. Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, Elliott P (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228-1235
12. MacDermot KD, Holmes A, Miners AH (2001a) Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis 24(Suppl 2):13-14
13. MacDermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750-760
14. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM, Witteman JC (2006) Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation 113:657-663
15. McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR (2005) Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol 46:1753-1760
16. Mourad JJ, Pannier B, Blacher J, Rudnichi A, Benetos A, London GM, Safar ME (2001) Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 59:1834-1841
17. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600-1607
18. Perkovic V, Nicholls K, De Caneva R, Centra E, Becker G (2003) Arterial stiffness is reduced by enzyme replacement therapy for Fabry's disease (abstract). Nephrol Dial Transplant 18(Suppl 4):631, W268
19. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, Eber B (2004) Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 109:184-189
20. West M, Nicholls K, Mehta A, Clarke JTR, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20:1132-1139
21. Zieman S, Melenovsky V, Kass DA (2005) Mechanisms, pathophysi-ology and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25:932-943
22. Zureik M, Safar M, Guize L (2002) Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 105:1202-1207